Wilding et al. 2021 — STEP 1: Semaglutide for Obesity

Once-weekly semaglutide 2.4mg achieved 14.9% weight loss over 68 weeks vs 2.4% placebo in adults with obesity; 69.1% achieved >=10% weight loss.

Abstract

Landmark trial showing 14.9% weight loss with semaglutide 2.4mg weekly vs 2.4% placebo over 68 weeks.

Key Findings

Once-weekly subcutaneous semaglutide 2.4 mg achieved 14.9% mean weight loss over 68 weeks vs 2.4% with placebo. 69.1% of participants achieved >=10% weight loss. Gastrointestinal adverse events were the most common side effect.

Study Design

Randomized controlled trial (STEP 1)